Company intelligence / Profile preview

Elixir Pharmaceuticals

Cambridge, Massachusetts, United Statesbloomberg.com ↗

Ownership: Private
Employees: ~34
Development stage: Preclinical

Overview

Elixir Pharmaceuticals was a Cambridge, MA-based biopharmaceutical company focused on developing drugs to treat and prevent metabolic and age-related diseases by targeting longevity genes. The company raised over $169M in venture funding but ultimately ceased operations. It had partnerships for drug discovery services but did not reach commercial stage with any products.

Therapeutic areas: OtherMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Evotec OAI for chemical/biological drug discovery services

Beyond the preview

Go deeper on Elixir Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elixir Pharmaceuticals.

Explore the full profile